H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Processa Pharmaceuticals (PCSA) to $1 from $2 and keeps a Buy rating on the shares. The firm cites equity dilution from the strategic investment for the target cut.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCSA:
- Processa Pharmaceuticals Relocates 2025 Stockholder Meeting
- Processa Pharmaceuticals Reports Increased Losses Amid Strategic Developments
- Processa Pharmaceuticals Raises $1.3M in Private Placement
- Processa secures strategic investment, evaluates crypto strategy
- Processa Pharmaceuticals Files Prospectus for Stock Sale